Add Company
Join Now

Reprieve Cardiovascular Revenue and Competitors

License our Company Data API

Milford, MA USA

Location

N/A

Total Funding

Medical Equip

Industry

Estimated Revenue & Valuation

  • Reprieve Cardiovascular's estimated annual revenue is currently $5M per year.(i)
  • Reprieve Cardiovascular's estimated revenue per employee is $228,182

Employee Data

  • Reprieve Cardiovascular has 22 Employees.(i)
  • Reprieve Cardiovascular grew their employee count by 10% last year.

Reprieve Cardiovascular's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP R&DReveal Email/Phone
3
VP Strategy and InnovationReveal Email/Phone
4
Director EuropeReveal Email/Phone
5
Managing Director and Chief Financial OfficerReveal Email/Phone
6
Director OperationsReveal Email/Phone
7
Field Clinical DirectorReveal Email/Phone
8
Director QualityReveal Email/Phone
9
Chief Operating OfficerReveal Email/Phone
10
Director Clinical AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M3613%N/AN/A
#2
$8.5M3629%N/AN/A
#3
$3M12-29%N/AN/A
#4
$5630M7477-11%$450MN/A
#5
$4.5M140%N/AN/A
#6
$7.2M5928%$29.6MN/A
#7
$14.3M13-72%N/AN/A
#8
$2.3M3194%$44MN/A
#9
$40.7M1459%N/AN/A
#10
$45.7M1490%N/AN/A
Add Company

What Is Reprieve Cardiovascular?

Reprieve Cardiovascular is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). The company's Reprieve technology is being investigated as an innovative fluid management therapy. Providing clinicians with the ability to precisely control a patient's fluid volume may both enable improved cardiac care, as well as, be instrumental in the decongestion of ADHF patients. Reprieve Cardiovascular is led by a seasoned management team with extensive experience in the medical device industry.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$5M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Reprieve Cardiovascular News

2022-04-19 - A Majority of People With HIV Have Asymptomatic COVID

The main aim of the REPRIEVE trial is to assess the effect of a cholesterol-lowering statin medication on cardiovascular disease outcomes...

2022-04-06 - A proteomic surrogate for cardiovascular outcomes that is ...

A reliable, individualized, and dynamic surrogate of cardiovascular risk, ... Reprieve Cardiovascular, 3ive, Renalytix, and Vifor in the past 3 years.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.9M22-4%N/A
#2
$7.9M220%N/A
#3
$3M22-8%N/A
#4
$2.5M22-8%N/A
#5
$2.9M2321%N/A